About Inovio Pharmaceuticals
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative
|
|
|
1-10 employees
View all Inovio Pharmaceuticals employees
|
|
IT Services and IT Consulting
|
|
8585970451
|
|
Blue Bell, Pennsylvania
|
|
1983
|
Inovio Pharmaceuticals Alternatives
Frequently Asked Questions about Inovio Pharmaceuticals
The decision makers in Inovio Pharmaceuticals are Karen Richards, Xuefei Shen, etc. Click to Find Inovio Pharmaceuticals decision makers emails.
Inovio Pharmaceuticals Staff Directory
Search Inovio Pharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
